Duloxetine
Product Images NDC 68151-4727

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68151-4727). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (68151 4727)

Label for Duloxetine 60 mg oral capsule, showing the brand name Cymbalta and generic name duloxetine. The label includes manufacturing information by Lilly, lot number C190849A, and expiration date 07/14. The product NDC is 68151-4727, with a barcode and Rx only designation.*

FDA Label Image

Figure 1 (Cag Pi 1v1)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine (DLX) at 60 mg BID, 60 mg QD, 20 mg QD, and placebo. The graph compares the pain improvement percentages across these treatment groups, with Duloxetine doses demonstrating higher patient improvement percentage curves than placebo.*

FDA Label Image

Figure 2 (Cag Pi 2v1)

A line chart depicting percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: DLX 60mg BID, DLX 60mg QD, and Placebo. The x-axis shows percent improvement in pain from baseline, ranging from >0 to 100%, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. The DLX 60mg BID and DLX 60mg QD groups show higher patient improvement percentages compared to Placebo at most percent improvement levels.*

FDA Label Image

Figure 3 (Cag Pi 3v1)

A line chart showing the percentage of patients improved against percent improvement in pain from baseline. It compares three groups: Duloxetine (DLX) 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, over a range from 0% to 100% pain improvement. The chart illustrates the trend of patient improvement percentages for each group across various pain improvement levels.*

FDA Label Image

Figure 4 (Cag Pi 4v1)

A line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. The graph compares four groups: Duloxetine (DLX) 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. Each group is represented by a distinct symbol or line style, illustrating the percentage of patients achieving various levels of pain improvement.*

FDA Label Image

Figure 5 (Cag Pi 5v1)

A line graph comparing the percentage of patients improved by Duloxetine 60/120 mg once daily and placebo across different levels of pain improvement from baseline (BOCF). The y-axis shows the percentage of patients improved, ranging from 0 to 100%, and the x-axis shows percent improvement in pain, from greater than 0 to 100%. Two lines represent placebo and Duloxetine treatment groups, illustrating higher improvement percentages for Duloxetine at all pain improvement levels.*

FDA Label Image

Figure 6 (Cag Pi 6v1)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo groups. The graph shows Duloxetine consistently having higher patient improvement percentages across increasing pain improvement intervals from 0 to 100%.*

FDA Label Image

Figure 7 (Cag Pi 7v1)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine (DLX) 60/120 mg once daily and placebo. The graph shows two lines, one solid line with diamonds representing Duloxetine treatment and one dotted line with crosses for placebo, depicting patient improvement rates at various levels of pain improvement.*

FDA Label Image

Structural Formula (Cag Pi Chemstruct V1)

Chemical structure of Duloxetine hydrochloride showing its molecular arrangement including aromatic rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.